MAIA Biotechnology, Inc. is a cutting-edge, early stage biotech company, dedicated to developing targeted cancer therapies with novel mechanisms of action that are intended to meaningfully improve and extend the lives of patients with cancer. A privately-held company based in Chicago and Houston, MAIA is led by a passionate, principled and dynamic Management Team with significant drug development experience, committed to advancing promising agents into trials in humans in the next 3-5 years.
Our Pipeline
DGD-1202
DGD-1202, a mtEGFR degrader, is selectively effective in inducing phosphorylated-EGFR degradation in tumors, including tyrosine kinase inhibitors (TKI)-resistant tumors....
THIO
THIO (6-thio-dG) targets tumor cell DNA and causes damage to DNA ends (telomeres), resulting in the selective death of tumor...
MJC13
MJC13 targets the regulation of androgen receptor (AR) by binding to a recently identified regulatory surface on AR (BF3). MJC13 effectively...
GMC1
GMC1 is a FKBP52 co-chaperone-inhibitor for prostate cancer. GMC1 engages a new pharmacologic target, FKBP52 (FK506 binding protein), to inhibit...